# Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)

> **NCT03129061** · PHASE1 · COMPLETED · sponsor: **CellSight Technologies, Inc.** · enrollment: 15 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **DRUG:** [18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.
- **DRUG:** [18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.

## Key facts

- **NCT ID:** NCT03129061
- **Lead sponsor:** CellSight Technologies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-01
- **Primary completion:** 2022-12-01
- **Final completion:** 2022-12-01
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2022-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03129061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03129061, "Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03129061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*